Latest News and Press Releases
Want to stay updated on the latest news?
-
BOSTON, May 29, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
-
Conference Call Today at 8:30 a.m. EST COPENHAGEN, Denmark, May 25, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to...
-
First quarter 2018 total revenues of $21.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $20.6 million; a 96 percent increase compared to the first quarter of 2017Company...
-
BOSTON, May 07, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
-
Gregory Madison resigned as president and chief executive officer of the company and from its board of directorsJodie Morrison, current Keryx board member, named interim chief executive officerCompany...
-
BOSTON, April 19, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
-
Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation
AUSTIN, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease,...
-
BOSTON, April 04, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
-
BOSTON, March 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today...
-
Fourth quarter 2017 total revenues of $18.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $17.3 millionFull year 2017 total revenues of $60.6 million; net U.S. Auryxia product...